Literature DB >> 26897014

Neuro-oncology biotech industry progress report.

Shamik Chakraborty1,2, Imithri Bodhinayake3, Amrit Chiluwal4, David J Langer4,5, Rosamaria Ruggieri3, Marc Symons3, John A Boockvar3,4,5.   

Abstract

The Brain Tumor Biotech Center at the Feinstein Institute for Medical Research, in collaboration with Voices Against Brain Cancer hosted The Brain Tumor Biotech Summit at in New York City in June 2015. The focus was once again on fostering collaboration between neuro-oncologist, neurosurgeons, scientists, leaders from biotechnology and pharmaceutical industries, and members of the financial community. The summit highlighted the recent advances in the treatment of brain tumor, and specifically focused on targeting of stem cells and EGFR, use of prophage and immunostimulatory vaccines, retroviral vectors for drug delivery, biologic prodrug, Cesium brachytherapy, and use of electric field to disrupt tumor cell proliferation. This article summarizes the current progress in brain tumor research as presented at 2015 The Brain Tumor Biotech Summit.

Entities:  

Keywords:  Biotechnology; Brain tumors; Glioblastoma

Mesh:

Year:  2016        PMID: 26897014     DOI: 10.1007/s11060-016-2087-z

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.506


  41 in total

1.  A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study.

Authors:  James Schuster; Rose K Lai; Lawrence D Recht; David A Reardon; Nina A Paleologos; Morris D Groves; Maciej M Mrugala; Randy Jensen; Joachim M Baehring; Andrew Sloan; Gary E Archer; Darell D Bigner; Scott Cruickshank; Jennifer A Green; Tibor Keler; Thomas A Davis; Amy B Heimberger; John H Sampson
Journal:  Neuro Oncol       Date:  2015-01-13       Impact factor: 12.300

2.  Retroviral Replicating Vectors Deliver Cytosine Deaminase Leading to Targeted 5-Fluorouracil-Mediated Cytotoxicity in Multiple Human Cancer Types.

Authors:  Chris G Twitty; Oscar R Diago; Daniel J Hogan; Cindy Burrascano; Carlos E Ibanez; Douglas J Jolly; Derek Ostertag
Journal:  Hum Gene Ther Methods       Date:  2015-12-01       Impact factor: 2.396

3.  Dosimetric study of Cs-131, I-125, and Pd-103 seeds for permanent prostate brachytherapy.

Authors:  Ruijie Yang; Junjie Wang; Hongzhi Zhang
Journal:  Cancer Biother Radiopharm       Date:  2009-12       Impact factor: 3.099

4.  Multimodality therapy with a replication-conditional herpes simplex virus 1 mutant that expresses yeast cytosine deaminase for intratumoral conversion of 5-fluorocytosine to 5-fluorouracil.

Authors:  H Nakamura; J T Mullen; S Chandrasekhar; T M Pawlik; S S Yoon; K K Tanabe
Journal:  Cancer Res       Date:  2001-07-15       Impact factor: 12.701

Review 5.  Ligand-Independent EGFR Signaling.

Authors:  Gao Guo; Ke Gong; Bryan Wohlfeld; Kimmo J Hatanpaa; Dawen Zhao; Amyn A Habib
Journal:  Cancer Res       Date:  2015-08-17       Impact factor: 12.701

6.  Identification of TRAIL-inducing compounds highlights small molecule ONC201/TIC10 as a unique anti-cancer agent that activates the TRAIL pathway.

Authors:  Joshua E Allen; Gabriel Krigsfeld; Luv Patel; Patrick A Mayes; David T Dicker; Gen Sheng Wu; Wafik S El-Deiry
Journal:  Mol Cancer       Date:  2015-05-01       Impact factor: 27.401

7.  The angular structure of ONC201, a TRAIL pathway-inducing compound, determines its potent anti-cancer activity.

Authors:  Jessica Wagner; Christina Leah Kline; Richard S Pottorf; Bhaskara Rao Nallaganchu; Gary L Olson; David T Dicker; Joshua E Allen; Wafik S El-Deiry
Journal:  Oncotarget       Date:  2014-12-30

8.  TIC10/ONC201: a bend in the road to clinical development.

Authors:  Yoshimi Endo Greer; Stanley Lipkowitz
Journal:  Oncoscience       Date:  2015-02-20

9.  TIC10/ONC201 synergizes with Bcl-2/Bcl-xL inhibition in glioblastoma by suppression of Mcl-1 and its binding partners in vitro and in vivo.

Authors:  Georg Karpel-Massler; Maïmouna Bâ; Chang Shu; Marc-Eric Halatsch; Mike-Andrew Westhoff; Jeffrey N Bruce; Peter Canoll; Markus D Siegelin
Journal:  Oncotarget       Date:  2015-11-03

10.  Autologous tumor-derived heat-shock protein peptide complex-96 (HSPPC-96) in patients with metastatic melanoma.

Authors:  Omar Eton; Merrick I Ross; Mary Jo East; Paul F Mansfield; Nicholas Papadopoulos; Julie A Ellerhorst; Agop Y Bedikian; Jeffrey E Lee
Journal:  J Transl Med       Date:  2010-01-29       Impact factor: 5.531

View more
  1 in total

Review 1.  Glioblastoma Treatments: An Account of Recent Industrial Developments.

Authors:  Edouard Alphandéry
Journal:  Front Pharmacol       Date:  2018-09-13       Impact factor: 5.810

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.